Items per page
Sort by

Send to:

Choose Destination

Results: 8

Cited In for PubMed (Select 16606780)


Treatment strategies for multiple sclerosis: When to start, when to change, when to stop?

Gajofatto A, Benedetti MD.

World J Clin Cases. 2015 Jul 16;3(7):545-55. doi: 10.12998/wjcc.v3.i7.545. Review.


Conversion from radiologically isolated syndrome to multiple sclerosis.

Etemadifar M, Janghorbani M, Koushki MM, Etemadifar F, Esfahani MF.

Int J Prev Med. 2014 Nov;5(11):1379-86.


Treatment selection and experience in multiple sclerosis: survey of neurologists.

Hanson KA, Agashivala N, Wyrwich KW, Raimundo K, Kim E, Brandes DW.

Patient Prefer Adherence. 2014 Apr 3;8:415-22. doi: 10.2147/PPA.S53140. eCollection 2014.


Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis.

Lugaresi A, di Ioia M, Travaglini D, Pietrolongo E, Pucci E, Onofrj M.

Neuropsychiatr Dis Treat. 2013;9:893-914. doi: 10.2147/NDT.S45144. Epub 2013 Jun 24.


Proteomic strategies in multiple sclerosis and its animal models.

Elkabes S, Li H.

Proteomics Clin Appl. 2007 Oct 16;1(11):1393-1405.


Estimating Time to Event From Longitudinal Categorical Data: An Analysis of Multiple Sclerosis Progression.

Mandel M, Gauthier SA, Guttmann CR, Weiner HL, Betensky RA.

J Am Stat Assoc. 2007 Dec;102(480):1254-1266.


Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up.

Optic Neuritis Study Group.

Arch Neurol. 2008 Jun;65(6):727-32. doi: 10.1001/archneur.65.6.727.


Early prediction of the long term evolution of multiple sclerosis: the Bayesian Risk Estimate for Multiple Sclerosis (BREMS) score.

Bergamaschi R, Quaglini S, Trojano M, Amato MP, Tavazzi E, Paolicelli D, Zipoli V, Romani A, Fuiani A, Portaccio E, Berzuini C, Montomoli C, Bastianello S, Cosi V.

J Neurol Neurosurg Psychiatry. 2007 Jul;78(7):757-9. Epub 2007 Jan 12.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk